From the Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.
Horizon Blue Cross and Blue Shield (Horizon), Newark, New Jersey.
Allergy Asthma Proc. 2023 Sep 1;44(5):340-344. doi: 10.2500/aap.2023.44.230045.
Patients with severe uncontrolled asthma (SUA) overwhelmingly contribute to the economic burden of asthma and may require biologic therapy. However, the impact of the CoronaVirus Disease of 2019 (COVID-19) on asthma costs and biologic use has yet to be evaluated. The objective was to test the hypothesis that SUA costs and biologic use decreased during the pandemic. We analyzed medical costs and biologic use in patients with SUV from January 2017 to December 2021, by using claims data from a large managed care organization and electronic health record data from Robert Wood Johnson Barnabas Health, according to provider specialty. Of the 3817 managed care organization enrollees within Robert Wood Johnson Barnabas Health with a primary diagnosis of asthma, 348 were identified as having SUA. A nested sample of 151 patients revealed that 50% were managed by primary care physicians (PCP) and specialists, 43% by PCPs only, and 4% by specialists only. The total costs of the claims were $10.8 million over 5 years ($2.2 million per year), with 60% generated from patients seeing PCPs and specialists, 27% from PCPs only, and 15% from specialists only. During the pandemic, total average costs decreased for all care groups (34% PCP-only patients and 45% for both specialist-only and PCP and specialist patients). Inpatient and outpatient costs also decreased and were lowest for patients who saw specialists and highest for patients who saw PCPs and specialists. In contrast, prescription costs increased during the pandemic. Biologic use was steadily increasing until a twofold decrease was observed during the pandemic. Thirteen patients were on biologics: two were managed by PCPs, four by specialists, and seven by both. Inpatient and outpatient costs decreased during the COVID-19 pandemic, but prescription costs increased. Biologic use was increasing among patients with SUA before the pandemic but then drastically decreased and remained lower during the observational interval.
患有严重未控制哮喘(SUA)的患者极大地增加了哮喘的经济负担,可能需要接受生物治疗。然而,2019 年冠状病毒病(COVID-19)对哮喘成本和生物制剂使用的影响尚未得到评估。目的是检验假设,即在大流行期间,SUA 成本和生物制剂使用减少。我们根据医生专业,利用大型管理式医疗组织的索赔数据和罗伯特伍德约翰逊巴纳巴斯健康的电子健康记录数据,分析了 2017 年 1 月至 2021 年 12 月期间患有 SUV 的患者的医疗费用和生物制剂使用情况。在罗伯特伍德约翰逊巴纳巴斯健康的管理式医疗组织中,有 3817 名患有哮喘的主要诊断患者,其中 348 名被确定为患有 SUA。一个嵌套的 151 名患者样本显示,50%由初级保健医生(PCP)和专家管理,43%仅由 PCP 管理,4%仅由专家管理。5 年内索赔的总费用为 1080 万美元(每年 220 万美元),其中 60%来自 PCP 和专家就诊的患者,27%来自 PCP 就诊的患者,15%来自专家就诊的患者。在大流行期间,所有护理组的总平均费用均下降(仅 PCP 患者下降 34%,仅专家和 PCP 和专家患者下降 45%)。住院和门诊费用也下降,仅专家就诊的患者最低,PCP 和专家就诊的患者最高。相比之下,处方费用在大流行期间增加。生物制剂的使用稳步增加,直到大流行期间观察到两倍的下降。有 13 名患者使用生物制剂:两名由 PCP 管理,四名由专家管理,七名由 PCP 和专家共同管理。在 COVID-19 大流行期间,住院和门诊费用下降,但处方费用增加。在大流行之前,患有 SUA 的患者的生物制剂使用量一直在增加,但随后急剧下降,在观察期内仍保持较低水平。